Drug Development Services

Chemical Bioanalysis in Drug Development

We have offered high-quality non clinical drug development services for over 30 years to clients in the pharmaceutical, biotechnology, and chemical industries. Our integrated capabilities include drug metabolism and pharmacokinetics (DMPK), toxicology, bioanalytical services, and analytical and formulation development services.

The goal of our nonclinical studies is to help determine which compounds have the greatest probability of success, and to build a solid scientific foundation for further development. We provide timely, accurate, and accessible data as well as scientific consulting to optimize the progress of your compound. Our experienced scientists offer standard and customized study designs as well as issue-driven research capabilities.

Focus Areas

  • Drug Metabolism and Pharmacokinetics (DMPK)
    Comprehensive selection of in vivo and in vitro DMPK services; standard regulatory-driven study designs and innovative approaches to unique drug development issues
  • Toxicology
    Development of appropriate biological models to safety test client compounds; standard preclinical studies to evaluate the safety of new drug candidates; specialty studies with unique biological models to assess drug efficacy and ensure quick and efficient IND submission
  • Bioanalytical Chemistry Services
    Support and consultation to major pharmaceutical companies; metabolite identification; clinical trial sample analysis; LC/MS methods development and validation; cGMP release of finished products; DMPK and toxicology support
  • Analytical and Formulation Development Services
    Analytical support, contract formulation development, and consultation to pharmaceutical, chemical, and biotechnology companies; thermal analysis, solubility, structure, stability, moisture content, particle morphology, and other studies
  • Biotherapeutics and Biologics Services
    Method development and product characterizations supporting in-process analysis and lot release for vaccines and other biologics to demonstrate identity, purity, and quality
  • Metabolomics Research
    Description of the role RTI plays as the Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC), funded by the National Institutes of Health and directed by Susan Sumner, PhD

Principal Investigators

Spotlight
Designer drug research

Science and the War on Designer Drugs

With funding from the National Institute on Drug Abuse, RTI scientists are applying their expertise to help address the global challenge of clandestinely produced drugs that are pharmacologically similar to a controlled substance but are not illegal. Read more